Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT001 plus whole brain radiation therapy for metastatic brain cancer
ACTRN12621000093886Phase 2Terminated
- Sponsor
- Accendatech
- Start
- Oct 2021
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dimethylaminomicheliolide in brain metastases, sponsored by Accendatech. Started Oct 2021; status: terminated.
02
Drugs
dimethylaminomicheliolide
03
Conditions
brain metastases
Beyond the preview
Go deeper on ACTRN12621000093886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000093886.